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Abstract
Patients with chronic hypoxaemia develop secondary polycythaemia that improves oxygen-carrying capacity. Therefore, normal
haemoglobin and haematocrit values in the presence of chronic arterial hypoxaemia in cystic fibrosis constitute ‘relative anaemia’.
We sought to determine the cause of this relative anaemia in patients with cystic fibrosis. We studied haematological indices and
oxygen saturation in healthy volunteers (ns17) and in adult patients with cystic fibrosis (ns15). Patients with cystic fibrosis
had lower resting arterial oxygen saturation when compared with normal volunteers (P-0.0001), and exercise led to a greater
reduction in arterial oxygen saturation (P-0.0001). However, haemoglobin and haematocrit values in patients with cystic fibrosis
did not significantly differ from normal volunteers. Serum iron (Ps0.002), transferrin (Ps0.02), and total iron-binding capacity
(Ps0.01) were lower in patients with cystic fibrosis. There were no significant differences in serum ferritin, percentage iron
saturation, serum erythropoietin or red cell volume between the groups. The data presented demonstrate a characteristic picture
of anaemia of chronic disease in adult patients with cystic fibrosis, except for normal haemoglobin and haematocrit values.
Normal haemoglobin and haematocrit values in patients with cystic fibrosis appear to represent a combination of the effects of
arterial hypoxaemia promoting polycythaemia, counterbalanced by chronic inflammation promoting anaemia of chronic disease.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Patients with chronic hypoxaemia develop a physio-
logically appropriate secondary polycythaemia that
improves oxygen-carrying capacity w1x. Hypoxaemia is
compensated by an increase in the haemoglobin concen-
tration and a rise in the haematocrit. The resulting
increased erythropoiesis may lead to iron deficiency.
Chronic pulmonary inflammation and tissue destruc-
tion leads to hypoxaemia in patients with cystic fibrosis.
Although arterial hypoxaemia is usually moderate until
pulmonary destruction is advanced, polycythaemia is
rarely observed. Normal haemoglobin and haematocrit
values in the presence of chronic arterial hypoxaemia
 Previously presented as: Is a ‘normal’ haemoglobin value in a
patient with cystic fibrosis normal? At the European Cystic Fibrosis
Conference, Vienna, Austria, June 2001.
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constitute ‘relative anaemia’. It might be expected that
analysis of haematological indices in hypoxaemic
patients with cystic fibrosis might reveal sub-clinical
iron deficiency, due to increased erythropoietic iron
requirements. However, anaemia resulting from sup-
pressed erythropoiesis is also observed in diseases char-
acterised by chronic inflammation — the anaemia of
chronic disease.
We sought to determine whether relative anaemia in
cystic fibrosis is caused by iron deficiency or the
mechanisms responsible for anaemia of chronic disease,
by comparing haematological indices and oxygen satu-
ration with normal volunteers.
2. Materials and methods
2.1. Study subjects
A total of 17 healthy volunteers and 15 adult patients
with stable cystic fibrosis were studied. Volunteers were
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Table 1
Oxygen saturation and haematological indices in normal control subjects and cystic fibrosis patients
Control Cystic fibrosis P value
(ns17) (ns15)
Age (years) 26.1"0.95 24.6"1.69 NS
O saturation (rest) (%)2 98.2"0.15 90.9"0.58 -0.0001
O saturation (exercise) (%)2 98.6"0.15 89.5"0.96 -0.0001
Change (%) q0.39"0.24 y1.52"0.75 0.03
Haemoglobin (12–18 g dl )y1 13.3"0.27 13.8"0.35 NS
Haematocrit (0.36–0.46 l l )y1 0.41"0.01 0.43"0.01 NS
Vitamin B (150–750 ng l )y112 411"39.5 716"107.9 0.01
Folate (2.4–20 ng ml )y1 7.62"0.53 15.81"1.39 -0.0001
Ferritin (17–324 ng ml )y1 44.2"11.5 70.1"15.3 NS
Iron (8–28 mmol l )y1 18.8"1.91 10.7"1.26 0.002
Transferrin (1.8–3.2 g l )y1 2.87"0.14 2.38"0.14 0.02
TIBC (42–80 mmol l )y1 70"2.25 59.1"3.40 0.01
Transferrin saturation (%) 26.49"2.90 19.4"2.70 NS
Erythropoietin (10–25 mU ml )y1 13.6"1.73 12"1.34 NS
Red cell volume (20–35 ml kg )y1 25.88"0.99 27.8"1.11 NS
Data are presented as mean"S.E.M. TIBC, total iron-binding capacity; NS, not significant. Normal ranges (parentheses) when different in
males and females are expressed as the lowest to the highest values.
non-smokers with no history of cardiopulmonary dis-
ease. Patients with cystic fibrosis were symptomatically
well and had mild to moderate pulmonary disease (mean
FEV 62.7% predicted, S.E.M. 1.28, range 52–70%).1
Subjects were recruited from an adult cystic fibrosis
clinic according to their willingness to participate in the
study. All were taking oral pancreatic enzyme, vitamin
and mineral supplements (including cyanocobalamin 0.5
mg, folic acid 0.1 mg and ferrous sulfate 25 mg daily).
None were receiving parenteral vitamin B replacement.12
Informed consent was obtained from each subject, and
the study conformed to the criteria of the Hospital Ethics
in Research Committee.
2.2. Methods
Blood was taken from all subjects for determination
of haemoglobin concentration, haematocrit, red cell
volume, serum vitamin B concentration, red-cell folate12
concentration, serum ferritin, iron, transferrin, total iron-
binding capacity, percentage iron saturation and serum
erythropoietin. Red-cell volume estimation was based
on the standard radioactive Cr-sodium chromate meth-51
od using approximately 1 MBq Cr w2x. Oxygen satu-51
ration was measured at rest using a pulse oximeter. The
patients had oxygen saturation measured on three occa-
sions at 1-min intervals and the average value was used.
Subjects were then exercised on an exercise treadmill
until they attained their maximum heart rate predicted
or to the limit of exercise tolerance, and oxygen satu-
ration was again measured as above using pulse oxi-
metry after exercise. Arterial blood gases were not
analysed.
2.3. Analysis
Results were compared using the Instat and Prism
GraphPad statistical software packages (San Diego,
CA). Data were tested for normality using the Kolmo-
gorov–Smirnov (KS) test. The Mann–Whitney test was
used to determine differences between non-parametric
data. The unpaired t-test was used to determine differ-
ences between parametric data. All P values are based
on two-tailed tests. A P value -0.05 was considered
significant.
3. Results
Normal volunteers and patients with cystic fibrosis
were well matched for age. The data presented suggest
that adult patients with cystic fibrosis have significantly
lower resting arterial oxygen saturation when compared
with normal volunteers (P-0.0001) (Table 1). Exercise
in these patients leads to a greater reduction in arterial
oxygen saturation than in normal control subjects (P-
0.0001). However, haemoglobin and haematocrit values
did not significantly differ from normal volunteers.
Serum vitamin B (Ps0.01) and red cell folate (P-12
0.0001) concentrations were significantly higher than
those of normal patients. However, serum iron (Ps
0.002), transferrin (Ps0.02), and total iron-binding
capacity (Ps0.01) were significantly lower in patients
with cystic fibrosis. There were no significant differenc-
es in serum ferritin, percentage iron saturation, serum
erythropoietin or red cell volume.
4. Discussion
The data presented demonstrate a characteristic pic-
ture of anaemia of chronic disease in adult patients with
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cystic fibrosis, with normal serum ferritin and transferrin
saturation, but low serum iron (in spite of dietary iron
supplementation) and iron-binding capacity w3x. How-
ever, these patients had haemoglobin and haematocrit
values that did not significantly differ from normal
control subjects.
Previous studies have suggested that patients with
cystic fibrosis are able to compensate for hypoxaemia
by increasing red blood cell mass, but that an expanded
plasma volume prevents a detectable rise in haematocrit
w4x. We found no significant differences in red cell mass
between normal volunteers and patients with cystic
fibrosis. However, the significant differences in resting
and exercise oxygen concentrations between normal
patients and those with cystic fibrosis suggest that
normal haemoglobin values observed in patients with
cystic fibrosis may result from the balance between
chronic pulmonary inflammation, promoting anaemia of
chronic disease, and hypoxaemia, promoting polycythae-
mia. The patients with cystic fibrosis that participated
in this study had mild or moderate pulmonary disease.
In patients with more severe pulmonary disease, this
balance may change in favour of anaemia or
polycythaemia.
Functional iron deficiency due to chronic inflamma-
tion has been noted to be common in adults and children
with cystic fibrosis in studies from the last two decades
w5,6x, and long-term consumption of pancreatic enzymes
by patients with cystic fibrosis may impair iron absorp-
tion and contribute to iron deficiency w7x. Patients with
cystic fibrosis who are iron-deficient respond to oral
iron replacement therapy w8x. Although the mean trans-
ferrin saturation in our study was lower in patients with
cystic fibrosis when compared to normal control subjects
(19.4 vs. 26.49%), this difference was not statistically
significant (Ps0.09). Our finding of the characteristic
haematological abnormalities of anaemia of chronic
disease, rather than iron deficiency, may reflect the
improved modern nutritional management of patients
with cystic fibrosis unmasking the true defect.
The transferrin receptor is a key protein for the
cellular uptake of transferrin iron w9x. Quantification of
the serum transferrin receptor can be helpful in differ-
entiating anaemia of chronic disease and iron-deficiency
anaemia w10x. Serum receptor levels significantly rise
with tissue iron deficiency. In contrast to serum ferritin,
it is not influenced by the acute phase response w11x. A
recent study of the use of soluble transferrin receptor
assay in patients with cystic fibrosis suggested that the
transferrin saturation was overestimating, and the ferritin
underestimating, iron deficiency in these patients w12x.
The introduction of a transferrin receptor assay in the
routine investigation of anaemia will help to differentiate
iron deficiency anaemia from anaemia of chronic
disease.
The importance of nutrition in cystic fibrosis has been
increasingly emphasised in recent years. Vitamin sup-
plements are routinely prescribed to patients with cystic
fibrosis w13x. Vitamin B and folate were supplemented12
at the time of study within a multivitamin preparation.
Patients with cystic fibrosis had levels of vitamin B12
and folic acid that were significantly higher than those
of normal control subjects. These data suggest that such
preparations are inappropriate in patients with cystic
fibrosis, and we have since adjusted daily vitamin
therapy in patients to a more specific fat-soluble vitamin
preparation.
Anaemia is common in patients with chronic infec-
tious, inflammatory and neoplastic disorders. Many cyto-
kines involved in the chronic acute phase response have
an inhibitory activity on erythroid colony formation in
vitro. A characteristic finding in the disorders associated
with anaemia of chronic disease is increased production
of the cytokines that mediate the immune or inflamma-
tory response, such as tumour necrosis factor, interleu-
kin-1, interleukin-6 and the interferons. All the processes
involved in the development of anaemia of chronic
disease can be attributed to these cytokines, including
shortened red-cell survival, blunted erythropoietin
response to anaemia, impaired erythroid colony forma-
tion in response to erythropoietin and abnormal mobilis-
ation of reticuloendothelial iron stores w14x. The
underlying diversion of iron traffic leads to the with-
holding of iron from microbes, as well as from erythroid
precursors, and probably evolves as a cytokine-mediated
defence against microbial pathogens w15x. The circula-
tion of iron to the storage compartment in the reticu-
loendothelial system results in hypoferraemia and
hyperferritinaemia. Tumour necrosis factor, possibly via
induction of interleukin-6, and interferon-gamma induce
hypoferraemia, which may in part result from a decrease
in tissue iron release based on a primary stimulation of
ferritin synthesis w16x. It seems likely that these mech-
anisms explain the ‘relative anaemia’ observed in
patients with cystic fibrosis. Enhanced macrophage pro-
duction of proinflammatory cytokines and decreased
production of the regulatory molecule interleukin-10
have important roles in the pathogenesis of CF lung
disease w17x, and increased plasma tumour necrosis
factor is a feature of the near continuous inflammatory
response in cystic fibrosis w18x.
Approaches to the therapy of anaemia of chronic
disease in conditions such as rheumatoid arthritis include
tumour necrosis factor-alpha blockade with a chimeric
monoclonal antibody w19x or recombinant human eryth-
ropoietin treatment w20x. Response to erythropoietin
appears to be dependent on the availability of iron and
the degree of inflammation. If erythropoietin treatment
is considered, iron deficiency should always be corrected
and strenuous efforts should have been made to control
the disease itself. However, it seems that these treatment
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modalities would be inappropriate in patients with cystic
fibrosis, as haemoglobin values are usually maintained
within the normal range. Improved control of pulmonary
inflammation in cystic fibrosis in the future may reverse
the tendency to subclinical anaemia of chronic disease.
The authors conclude that normal haemoglobin and
haematocrit values observed in patients with cystic
fibrosis represent a combination of mild arterial hypox-
aemia, leading to a tendency to polycythaemia, and
chronic inflammation, leading to a tendency to anaemia
of chronic disease. This study was performed on a small
number of patients with cystic fibrosis with mildy
moderate pulmonary disease and borderline hypoxia.
Larger-scale studies might clarify whether patients with
more severe pulmonary disease and hypoxia might lean
toward a polycythaemic or anaemic tendency, depending
on the balance between anaemia of chronic disease and
the hypoxaemic drive towards polycythaemia.
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